One Stock Is Dragging Down the S&P 500's Earnings Growth
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
BAR HARBOR, Maine and MOUNTAIN VIEW, Calif., May 10, 2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotec
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 9 unusual trades.Delving into the details, we found
Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
Gilead's Kite, Arcellx Share Phase 3 Trial Design for CAR-T Multiple Myeloma Asset
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
Gilead Sciences | 10-Q: Quarterly report
Gilead Sciences Options Spot-On: On May 8th, 158.63K Contracts Were Traded, With 317.37K Open Interest
On May 8th ET, $Gilead Sciences(GILD.US)$ had active options trading, with a total trading volume of 158.63K options for the day, of which put options accounted for 96.73% of the total transactions, a
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return of 11.89%. Currently, Gilead Sciences has a market c
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
NORTHAMPTON, MA / ACCESSWIRE / May 7, 2024 / James had been free from using drugs for a decade when a routine test at his local health center revealed he had hepatitis C (HCV).James was one of many pe
Apple's $110B Buyback Is Larger Than the Market Caps of 418 S&P 500 Stocks
Gilead Sciences Unusual Options Activity For May 06
Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 13 unusual trades.Delving into the details, we foun
How Is The Market Feeling About Gilead Sciences?
Gilead Sciences's (NYSE:GILD) short percent of float has risen 4.62% since its last report. The company recently reported that it has 22.57 million shares sold short, which is 1.81% of all regular sha
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Forbes Has Listed Gilead as One of America's Best Employers for Diversity
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead SciencesForbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not on
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating
Gilead Sciences (GILD) has an average outperform rating and price target range of $69 to $121, according to analysts polled by Capital IQ. Price: 65.33, Change: -0.19, Percent Change: -0.28
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
No Data